In the study (Emerging-CTONG 1103) involving IIIA (N2) resectable NSCLC patients with EGFR alterations, investigators examined the efficacy of neoadjuvant/adjuvant erlotinib and gemcitabine plus cisplatin (GC chemotherapy). Here, EGFR is linked to non-small cell lung carcinoma.